Talzenna Capsule
Product Images NDC 63539-295
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Talzenna (NDC 63539-295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Talzenna 02)
The text describes a chart that shows the progression-free survival probability over time for the medication TALZENNA in comparison to chemotherapy. The chart shows the number of patients at risk, and the time is measured in months. The number of patients at risk decreases over time for both treatments.*
Talzenna 02a
Logo (Talzenna 03)
Logo (Talzenna 04)
Principal Display Panel (1 mg Capsule Bottle Label)
Principal Display Panel (1 mg Capsule Bottle Carton)
Talzenna® is a medication available in capsule form which contains talazoparib. These capsules are not available for sale and are provided as a professional sample only. Each capsule contains ampoules which are equivalent to 453 g of talazoparib tosyfate. The capsules are distributed by U.S. Pharmaceuticals and are made in Germany. The dosage and usage instructions can be found in the accompanying prescribing information. The lot/exp number is not readable from the text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.